UBS Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

UBS Group’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,800	Closed	-$928K	–	10416
2023 Q4	$928K	Buy	15,800 +4,800	+44%	+$270K	﹤0.01%	4565
2023 Q3	$479K	Buy	+11,000	New	+$393K	﹤0.01%	4680
2023 Q1	–	Sell	-19,000	Closed	-$861K	–	10905
2022 Q4	$861K	Buy	+19,000	New	+$1.23M	﹤0.01%	4213
2022 Q1	–	Sell	-6,000	Closed	-$880K	–	11178
2021 Q4	$880K	Buy	6,000 +3,200	+114%	+$497K	﹤0.01%	4503
2021 Q3	$495K	Buy	+2,800	New	+$450K	﹤0.01%	4745

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's MRTX Position: Q1 2024 in Review

UBS Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 51,945 shares — an estimated $3.05M sold.

UBS Group first reported a position in MRTX in Q4 2014 and held it in 37 quarters. The position peaked at $7.42M in Q4 2018. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

UBS Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
UBS Group sold 51,945 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.05M.
UBS Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2014 and held it in 37 quarters.
UBS Group's Mirati Therapeutics, Inc. Common Stock position peaked at $7.42M in Q4 2018.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.